NCT02460679View on ClinicalTrials.gov

Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 14, 2016

Primary Completion Date

February 23, 2018

Study Completion Date

February 23, 2018

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

EPI-589

An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.

Trial Locations (3)

90048

Cedar's Sinai, Los Angeles

94115

California Pacific Medical Center, San Francisco

97213

Providence Brain and Spine Institute ALS Center, Portland

Sponsors

Lead Sponsor

PTC Therapeutics
All Listed Sponsors
lead

PTC Therapeutics

INDUSTRY